Is Achilles Therapeutics Stock a Good Investment?
Achilles Therapeutics Investment Advice | ACHL |
- Examine Achilles Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Achilles Therapeutics' leadership team and their track record. Good management can help Achilles Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Achilles Therapeutics' business and its evolving consumer preferences.
- Compare Achilles Therapeutics' performance and market position to its competitors. Analyze how Achilles Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Achilles Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Achilles Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Achilles Therapeutics PLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Achilles Therapeutics PLC is a good investment.
Sell | Buy |
Strong Hold
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Achilles Therapeutics Stock
Researching Achilles Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 62.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Achilles Therapeutics PLC recorded a loss per share of 1.59. The entity had not issued any dividends in recent years.
To determine if Achilles Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Achilles Therapeutics' research are outlined below:
| Achilles Therapeutics has some characteristics of a very speculative penny stock | |
| Achilles Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Achilles Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Achilles Therapeutics plc Shares Bought by BML Capital Management LLC |
Achilles Therapeutics Quarterly Cost Of Revenue |
|
Achilles Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Achilles Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Achilles Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Achilles Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Achilles Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-10 | 2023-03-31 | -0.4 | -0.44 | -0.04 | 10 | ||
2022-05-09 | 2022-03-31 | -0.5 | -0.45 | 0.05 | 10 | ||
2022-08-09 | 2022-06-30 | -0.56 | -0.44 | 0.12 | 21 | ||
2021-11-09 | 2021-09-30 | -0.48 | -0.34 | 0.14 | 29 | ||
2024-05-08 | 2024-03-31 | -0.46 | -0.3 | 0.16 | 34 | ||
2023-03-07 | 2022-12-31 | -0.41 | -0.61 | -0.2 | 48 | ||
2022-11-08 | 2022-09-30 | -0.55 | -0.32 | 0.23 | 41 | ||
2024-02-29 | 2023-12-31 | -0.14 | -0.46 | -0.32 | 228 |
Know Achilles Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Achilles Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Achilles Therapeutics PLC backward and forwards among themselves. Achilles Therapeutics' institutional investor refers to the entity that pools money to purchase Achilles Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 61.4 K | Xtx Topco Ltd | 2024-06-30 | 51.7 K | Two Sigma Advisers, Llc | 2024-06-30 | 23.5 K | Virtu Financial Llc | 2024-06-30 | 22.8 K | Geode Capital Management, Llc | 2024-06-30 | 21.6 K | Two Sigma Investments Llc | 2024-06-30 | 21.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 17.9 K | Baader Bank Inc | 2024-06-30 | 12.4 K | Hrt Financial Llc | 2024-06-30 | 10.9 K | Syncona Portfolio Ltd. | 2024-06-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Achilles Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.41 M.Market Cap |
|
Achilles Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.49) | (0.51) |
Determining Achilles Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Achilles Therapeutics is a good buy. For example, gross profit margin measures Achilles Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Achilles Therapeutics' profitability and make more informed investment decisions.
Evaluate Achilles Therapeutics' management efficiency
Achilles Therapeutics PLC has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4422) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.45. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Achilles Therapeutics' Intangibles To Total Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.03 this year, although the value of Other Assets will most likely fall to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.56 | 3.38 | |
| Tangible Book Value Per Share | 3.56 | 3.38 | |
| Enterprise Value Over EBITDA | 1.30 | 1.36 | |
| Price Book Value Ratio | 0.25 | 0.24 | |
| Enterprise Value Multiple | 1.30 | 1.36 | |
| Price Fair Value | 0.25 | 0.24 | |
| Enterprise Value | -149 M | -141.5 M |
Examining the leadership quality of Achilles Therapeutics PLC offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 1.344 |
Basic technical analysis of Achilles Stock
As of the 13th of November 2024, Achilles Therapeutics shows the risk adjusted performance of 0.0931, and Mean Deviation of 1.99. Achilles Therapeutics PLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Achilles Therapeutics PLC downside variance, kurtosis, as well as the relationship between the treynor ratio and standard deviation to decide if Achilles Therapeutics PLC is priced correctly, providing market reflects its regular price of 1.01 per share. Given that Achilles Therapeutics is a hitting penny stock territory we recommend to closely look at its total risk alpha.Achilles Therapeutics' Outstanding Corporate Bonds
Achilles Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Achilles Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Achilles bonds can be classified according to their maturity, which is the date when Achilles Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACE INA HLDGS Corp BondUS00440EAH09 | View | |
| ACE INA HLDGS Corp BondUS00440EAQ08 | View | |
| ACE INA HLDGS Corp BondUS00440EAW75 | View | |
| ACE INA HLDGS Corp BondUS00440EAV92 | View | |
| ACE INA HLDGS Corp BondUS00440EAS63 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Achilles Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Achilles Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0931 | |||
| Market Risk Adjusted Performance | 0.3805 | |||
| Mean Deviation | 1.99 | |||
| Semi Deviation | 1.61 | |||
| Downside Deviation | 2.49 | |||
| Coefficient Of Variation | 907.71 | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.53 | |||
| Information Ratio | 0.0729 | |||
| Jensen Alpha | 0.2793 | |||
| Total Risk Alpha | (0.45) | |||
| Sortino Ratio | 0.1325 | |||
| Treynor Ratio | 0.3705 | |||
| Maximum Drawdown | 38.16 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 3.03 | |||
| Downside Variance | 6.21 | |||
| Semi Variance | 2.6 | |||
| Expected Short fall | (3.13) | |||
| Skewness | 5.61 | |||
| Kurtosis | 38.83 |
| Risk Adjusted Performance | 0.0931 | |||
| Market Risk Adjusted Performance | 0.3805 | |||
| Mean Deviation | 1.99 | |||
| Semi Deviation | 1.61 | |||
| Downside Deviation | 2.49 | |||
| Coefficient Of Variation | 907.71 | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.53 | |||
| Information Ratio | 0.0729 | |||
| Jensen Alpha | 0.2793 | |||
| Total Risk Alpha | (0.45) | |||
| Sortino Ratio | 0.1325 | |||
| Treynor Ratio | 0.3705 | |||
| Maximum Drawdown | 38.16 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 3.03 | |||
| Downside Variance | 6.21 | |||
| Semi Variance | 2.6 | |||
| Expected Short fall | (3.13) | |||
| Skewness | 5.61 | |||
| Kurtosis | 38.83 |
Consider Achilles Therapeutics' intraday indicators
Achilles Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Achilles Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Achilles Therapeutics time-series forecasting models is one of many Achilles Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Achilles Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Achilles Stock media impact
Far too much social signal, news, headlines, and media speculation about Achilles Therapeutics that are available to investors today. That information is available publicly through Achilles media outlets and privately through word of mouth or via Achilles internal channels. However, regardless of the origin, that massive amount of Achilles data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Achilles Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Achilles Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Achilles Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Achilles Therapeutics alpha.
Achilles Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Achilles Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Achilles Therapeutics Corporate Management
| Sergio Quezada | Founder Officer | Profile | |
| Daniel Hood | General Secretary | Profile | |
| Tariq Ahmed | Executive People | Profile | |
| James Taylor | Chief Officer | Profile | |
| Julia Wilson | Head Communications | Profile | |
| Lee Stern | Vice Communications | Profile | |
| FMEDSCI MD | Founder | Profile |
Already Invested in Achilles Therapeutics PLC?
The danger of trading Achilles Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Achilles Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Achilles Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Achilles Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Achilles Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.